Sodium Stibogluconate
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Sodium Stibogluconate: From Leishmaniasis to Drug-Induced Osteoporosis
One-Sentence Summary
Sodium stibogluconate is a pentavalent antimonial medicine originally used to treat leishmaniasis. The TxGNN model predicts it may be effective for drug-induced osteoporosis, but no clinical trials and no publications currently support this prediction, so it rests on computational modelling alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Leishmaniasis |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 0.9956 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data |
| Number of Listed Products | 2 (valid: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Sodium stibogluconate is a pentavalent antimonial whose efficacy in leishmaniasis is established. No mechanistic link to drug-induced osteoporosis is documented in the supplied data.
As general background knowledge (not part of the supplied data), antimonials are known to inhibit protein tyrosine phosphatases such as SHP-1, SHP-2 and PTP1B. In theory, this could modulate bone-cell signalling in osteoclasts or osteoblasts, for example through RANKL or insulin/IGF pathways. This is speculative and has no support from the evidence gathered here.
The very high TxGNN score (0.9956) is a computational prediction only, with no trials or literature to corroborate it. Antimonials also carry known toxicity, including cardiotoxicity, pancreatitis and hepatotoxicity. These risks weigh heavily against use in a chronic, non-life-threatening condition such as osteoporosis.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 204601 | Stibanate 100mg Injection | Vial of 30 ml injection | Not stated in the available data |
| 201378 | Sodium Stibogluconate Injection | Vial of 30 ml injection | Not stated in the available data |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score, with no clinical trials, no literature and no established mechanism. The known toxicity profile of antimonials makes the risk–benefit balance unfavourable for drug-induced osteoporosis without further evidence.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India product labels, needed for safety screening
- Mechanism of action data (for example from DrugBank) to assess any plausible link to bone metabolism
- Preclinical evidence (in vitro or animal bone models) testing whether the drug affects bone formation or resorption
- A literature and trial search to confirm that no relevant studies exist
- Confirmation of route compatibility, since the drug is currently available only as an injection
- A risk–benefit assessment against existing osteoporosis therapies, given the known cardiac, pancreatic and hepatic toxicity
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.